CDK4 and CDH1-related diffuse gastric and lobular breast cancer syndrome: In the pre‐CDK4/6i era, to overcome the increased activation of the MTORC1 pathway during acquisition of CDK4/6i resistance, patients with advanced or metastatic LBC were treated with various FDA‐approved MTORC1 inhibitors, such as everolimus.